For intravenous injection after reconstitution only
Table 1 provides dosage guidelines for the control and prevention of bleeding episodes in hemophilia A patients. Dosing should aim at maintaining a plasma factor VIII activity level at or above the plasma levels (in IU/dL or in % of normal) outlined in the table.
Table 1: Dosage Guidelines for Patients with Hemophilia A 
Table 2: Dosage Guidelines for Patients with von Willebrand Disease (Except Type 3 Subjects Undergoing Major Surgery) 
Figure 1, 2, 3, 4 , 5, 6 , 7and 8   
For intravenous use after reconstitution only
